Please Wait.....
Report
Saudi Arabia Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-05-01 I 71 Pages I Allied Market Research
The Saudi Arabia radiopharmaceuticals market is projected to register a healthy CAGR during the forecast period. The market growth is attributed to increasing prevalence of cancer, opening of new diagnostic and treatment centers, and rising awareness on long-term health benefits of radiopharmaceuticals. Radiopharmaceuticals are used for the diagnosis and treatment of a wide range of diseases, such as cancer, cardiovascular diseases, and diabetes.
In Saudi Arabia, numerous government policies and public-private sector initiatives have been launched to strengthen the radiopharmaceuticals sector. These initiatives include increasing access to radiopharmaceuticals facilities and encouraging foreign direct investment in the medical and healthcare sector. The country is also taking efforts to promote local manufacturing and production of radiopharmaceuticals.
The Saudi Arabia radiopharmaceuticals market is driven by the increasing prevalence of cancer and the rising demand for imaging procedures. Moreover, the rising awareness about the long-term health benefits offered by diagnostic imaging and treatment technologies is driving the growth of the radiopharmaceuticals market in the country. Furthermore, increasing healthcare expenditure in the country is expected to boost the growth of the radiopharmaceuticals market in the upcoming years.
A rapid increase in the prevalence of chronic illness like cancer, cardiovascular disease, and neurology is a crucial factor driving the radiopharmaceuticals market expansion. The increase in prevalence of target disease and surge in the need for diagnosis and treatment boosts the demand for radiopharmaceuticals. Radiopharmaceuticals are radioactive drugs that are used to detect and treat cancer cells. They are administered into the body and accumulate in cancerous tissues, allowing for the diagnosis and treatment of the disease.
On the contrary, limited reimbursement policies and high cost of radiopharmaceuticals are some of the factors hampering the market growth. Moreover, lack of skilled personnel, low availability of radiopharmaceuticals, and long working hours for radiopharmaceutical technicians are some of the other restraints hampering the growth of the radiopharmaceuticals market. The Saudi Arabia radiopharmaceuticals market players are expected to witness several growth opportunities in the upcoming years. The increasing number of radiopharmaceutical manufacturing companies and rising new product launches are expected to boost the market growth during the forecast period. Moreover, increasing R&D activities in the field of nuclear medicine and radiopharmaceuticals is likely to create lucrative growth opportunities for the radiopharmaceuticals market players.
The government is also focusing on the improvement of the regulatory framework, which will open new possibilities for market players. Furthermore, rising initiatives for the promotion of radiopharmaceuticals and imaging technologies along with the development of healthcare infrastructure in the country are expected to boost the growth of the market in the upcoming years.
The Porter's Five Forces Analysis of the Saudi Arabia radiopharmaceuticals market provides detailed insights into the competitive landscape of the market. It includes market competition from existing players, market entry barriers, threat of new entrants, bargaining power of suppliers and buyers, and threat of substitutes. The bargaining power of buyers and suppliers is high as the market is highly fragmented. Moreover, the presence of numerous regional and global players adds to the level of competition in the market. However, the presence of numerous barriers to entry limits the entry of new players in the market. The threat of substitutes is also high due to the availability of numerous alternatives to radiopharmaceuticals.
The SWOT analysis of the Saudi Arabia radiopharmaceuticals market does a detailed evaluation of the strengths, weaknesses, opportunities, and threats of the market. The market is supported by the increasing demand for imaging procedures and rising awareness about the long-term health benefits of radiopharmaceuticals. In addition, growing R&D activities along with the increasing number of radiopathology technicians in Saudi Arabia are also considered as the market growth driving factors. Lack of skilled personnel is one of the majors factors hampering the market growth.
The rising number of radiopharmaceutical manufacturing companies and new product launches are expected to create lucrative growth opportunities for the market players. In addition, rising initiatives for the promotion of radiopharmaceuticals and imaging technologies along with the development of healthcare infrastructure in the country is expected to drive the market growth. The Saudi Arabia radiopharmaceuticals market is expected to witness a considerable growth in the upcoming years due to increasing support from government bodies & healthcare providers and technological advancements in radiopharmaceutical production. Also, increasing investments in the medical sector are expected to encourage the use of radiopharmaceuticals. Government programs including the construction of nuclear medicine imaging and therapy facilities in major cities around the country are projected to boost the market expansion.
High cost of radiopharmaceuticals and limited reimbursement policies are projected to act as a restraining factors for the growth of the Saudi Arabia radiopharmaceuticals market. Market players are focusing on developing and launching new radiopharmaceuticals in this market. In 2018, a Saudi-based healthcare company, Al Amal, launched two new products, a Tc-99m-comprised radiopharmaceuticals and a cancer treatment radioisotope called Holmium-166. This led to an increase in the demand for radiopharmaceuticals in the Saudi Arabia radiopharmaceuticals market. SPIMACO is investing in R&D operation, to create and release cutting-edge of radiopharmaceutical market.
Jubilant Life Sciences, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Al-Azizia Panda United Company, National Oil Company (NOC), Saudi Chemical Company (SCC), Saudi Organics Industries, Saudi International Chemicals LTD (SICL), Saudi Arabian Petrochemical Company (Ibn Zahr), Al Fanar Pharmacy Company are some of the companies operating in te market.
Key Benefits For Stakeholders
-Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
-Analyze the key strategies adopted by major market players in the Saudi Arabia radiopharmaceuticals market.
-Assess and rank the top factors that are expected to affect the growth of the Saudi Arabia radiopharmaceuticals market.
-Top player positioning provides a clear understanding of the present position of market players.
-Detailed analysis of the Saudi Arabia radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Type
- Diagnostic
- Therapeutic
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Fluorine 18
- Iodine I
- Gallium 68
- Others
- Technetium 99m
By Application
- Cancer
- Cardiology
- Others
- Key Market Players
? Jubilant Life Sciences
? Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
? Gulf Pharmaceutical Industries (Julphar)
? Al-Azizia Panda United Company
? National Oil Company (NOC)
? Saudi Chemical Company (SCC)
? Saudi Organics Industries
? Saudi International Chemicals LTD (SICL)
? Saudi Arabian Petrochemical Company (Ibn Zahr)
? Al Fanar Pharmacy Company
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Jubilant Life Sciences
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Gulf Pharmaceutical Industries (Julphar)
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Al-Azizia Panda United Company
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. National Oil Company (NOC)
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Saudi Chemical Company (SCC)
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Saudi Organics Industries
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Saudi International Chemicals LTD (SICL)
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Saudi Arabian Petrochemical Company (Ibn Zahr)
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Al Fanar Pharmacy Company
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. JUBILANT LIFE SCIENCES: KEY EXECUTIVES
TABLE 06. JUBILANT LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 07. JUBILANT LIFE SCIENCES: OPERATING SEGMENTS
TABLE 08. JUBILANT LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 09. JUBILANT LIFE SCIENCES: KEY STRATERGIES
TABLE 10. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): KEY EXECUTIVES
TABLE 11. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): COMPANY SNAPSHOT
TABLE 12. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): OPERATING SEGMENTS
TABLE 13. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): PRODUCT PORTFOLIO
TABLE 14. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): KEY STRATERGIES
TABLE 15. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): KEY EXECUTIVES
TABLE 16. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): COMPANY SNAPSHOT
TABLE 17. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): OPERATING SEGMENTS
TABLE 18. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): PRODUCT PORTFOLIO
TABLE 19. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): KEY STRATERGIES
TABLE 20. AL-AZIZIA PANDA UNITED COMPANY: KEY EXECUTIVES
TABLE 21. AL-AZIZIA PANDA UNITED COMPANY: COMPANY SNAPSHOT
TABLE 22. AL-AZIZIA PANDA UNITED COMPANY: OPERATING SEGMENTS
TABLE 23. AL-AZIZIA PANDA UNITED COMPANY: PRODUCT PORTFOLIO
TABLE 24. AL-AZIZIA PANDA UNITED COMPANY: KEY STRATERGIES
TABLE 25. NATIONAL OIL COMPANY (NOC): KEY EXECUTIVES
TABLE 26. NATIONAL OIL COMPANY (NOC): COMPANY SNAPSHOT
TABLE 27. NATIONAL OIL COMPANY (NOC): OPERATING SEGMENTS
TABLE 28. NATIONAL OIL COMPANY (NOC): PRODUCT PORTFOLIO
TABLE 29. NATIONAL OIL COMPANY (NOC): KEY STRATERGIES
TABLE 30. SAUDI CHEMICAL COMPANY (SCC): KEY EXECUTIVES
TABLE 31. SAUDI CHEMICAL COMPANY (SCC): COMPANY SNAPSHOT
TABLE 32. SAUDI CHEMICAL COMPANY (SCC): OPERATING SEGMENTS
TABLE 33. SAUDI CHEMICAL COMPANY (SCC): PRODUCT PORTFOLIO
TABLE 34. SAUDI CHEMICAL COMPANY (SCC): KEY STRATERGIES
TABLE 35. SAUDI ORGANICS INDUSTRIES: KEY EXECUTIVES
TABLE 36. SAUDI ORGANICS INDUSTRIES: COMPANY SNAPSHOT
TABLE 37. SAUDI ORGANICS INDUSTRIES: OPERATING SEGMENTS
TABLE 38. SAUDI ORGANICS INDUSTRIES: PRODUCT PORTFOLIO
TABLE 39. SAUDI ORGANICS INDUSTRIES: KEY STRATERGIES
TABLE 40. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): KEY EXECUTIVES
TABLE 41. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): COMPANY SNAPSHOT
TABLE 42. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): OPERATING SEGMENTS
TABLE 43. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): PRODUCT PORTFOLIO
TABLE 44. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): KEY STRATERGIES
TABLE 45. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): KEY EXECUTIVES
TABLE 46. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): COMPANY SNAPSHOT
TABLE 47. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): OPERATING SEGMENTS
TABLE 48. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): PRODUCT PORTFOLIO
TABLE 49. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): KEY STRATERGIES
TABLE 50. AL FANAR PHARMACY COMPANY: KEY EXECUTIVES
TABLE 51. AL FANAR PHARMACY COMPANY: COMPANY SNAPSHOT
TABLE 52. AL FANAR PHARMACY COMPANY: OPERATING SEGMENTS
TABLE 53. AL FANAR PHARMACY COMPANY: PRODUCT PORTFOLIO
TABLE 54. AL FANAR PHARMACY COMPANY: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SAUDI ARABIA RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET
FIGURE 10. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. JUBILANT LIFE SCIENCES: NET SALES, 2020-2022*($MILLION)
FIGURE 22. JUBILANT LIFE SCIENCES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. JUBILANT LIFE SCIENCES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): NET SALES, 2020-2022*($MILLION)
FIGURE 25. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): NET SALES, 2020-2022*($MILLION)
FIGURE 28. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. AL-AZIZIA PANDA UNITED COMPANY: NET SALES, 2020-2022*($MILLION)
FIGURE 31. AL-AZIZIA PANDA UNITED COMPANY: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. AL-AZIZIA PANDA UNITED COMPANY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. NATIONAL OIL COMPANY (NOC): NET SALES, 2020-2022*($MILLION)
FIGURE 34. NATIONAL OIL COMPANY (NOC): REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. NATIONAL OIL COMPANY (NOC): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. SAUDI CHEMICAL COMPANY (SCC): NET SALES, 2020-2022*($MILLION)
FIGURE 37. SAUDI CHEMICAL COMPANY (SCC): REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. SAUDI CHEMICAL COMPANY (SCC): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. SAUDI ORGANICS INDUSTRIES: NET SALES, 2020-2022*($MILLION)
FIGURE 40. SAUDI ORGANICS INDUSTRIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. SAUDI ORGANICS INDUSTRIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): NET SALES, 2020-2022*($MILLION)
FIGURE 43. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): NET SALES, 2020-2022*($MILLION)
FIGURE 46. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. AL FANAR PHARMACY COMPANY: NET SALES, 2020-2022*($MILLION)
FIGURE 49. AL FANAR PHARMACY COMPANY: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. AL FANAR PHARMACY COMPANY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security